Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Background: For most patients with acute myeloid leukemia (AML) harboring a trisomy 8 an allogeneic hematopoietic stem cell transplantation (HSCT) is a suitable and recommended consolidation therapy. However, comparative outcome analyses between patients with and without trisomy 8 undergoing allogen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Donata Backhaus, Madlen Jentzsch, Lara Bischof, Dominic Brauer, Christina Wilhelm, Julia Schulz, Georg-Nikolaus Franke, Wolfram Pönisch, Vladan Vucinic, Uwe Platzbecker, Sebastian Schwind
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	trisomy 8 AML allogeneic HSCT MRD Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/797cdbdae53349c79acd6c63e269a2f6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:797cdbdae53349c79acd6c63e269a2f6
record_format	dspace
spelling	oai:doaj.org-article:797cdbdae53349c79acd6c63e269a2f62021-11-25T17:02:35ZRisk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation10.3390/cancers132256792072-6694https://doaj.org/article/797cdbdae53349c79acd6c63e269a2f62021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5679https://doaj.org/toc/2072-6694Background: For most patients with acute myeloid leukemia (AML) harboring a trisomy 8 an allogeneic hematopoietic stem cell transplantation (HSCT) is a suitable and recommended consolidation therapy. However, comparative outcome analyses between patients with and without trisomy 8 undergoing allogeneic HSCT have not been performed so far. Methods: We retrospectively analyzed clinical features, outcomes, and measurable residual disease (MRD) of 659 AML (12%, <i>n</i> = 81, with a trisomy 8) patients subjected to allogeneic HSCT as a consolidation therapy. Results: The presence of a trisomy 8 associated with a trend for higher age at diagnosis, AML of secondary origin, lower white blood cell counts at diagnosis, worse ELN2017 genetic risk, wild-type <i>NPM1</i>, and mutated <i>IDH1/2</i> and <i>JAK2</i>. Outcomes after allogeneic HSCT in the entire cohort did not differ between patients with a sole trisomy 8, trisomy 8 with additional cytogenetic aberrations or without a trisomy 8. A trisomy 8 did not affect outcomes within the three ELN2017 risk groups. In accordance with findings in unselected patient cohorts, persistent MRD at allogeneic HSCT in patients with a trisomy 8 identified individuals with a higher risk of relapse following allogeneic HSCT. Conclusions: Outcomes of trisomy 8 patients after allogeneic HSCT did not compare unfavorably to that of other AML patients following allogeneic HSCT. Rather than the presence or absence of a trisomy 8, additional genetic aberrations and MRD at HSCT define outcome differences and aid in informed treatment decisions.Donata BackhausMadlen JentzschLara BischofDominic BrauerChristina WilhelmJulia SchulzGeorg-Nikolaus FrankeWolfram PönischVladan VucinicUwe PlatzbeckerSebastian SchwindMDPI AGarticletrisomy 8AMLallogeneic HSCTMRDNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5679, p 5679 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	trisomy 8 AML allogeneic HSCT MRD Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	trisomy 8 AML allogeneic HSCT MRD Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Donata Backhaus Madlen Jentzsch Lara Bischof Dominic Brauer Christina Wilhelm Julia Schulz Georg-Nikolaus Franke Wolfram Pönisch Vladan Vucinic Uwe Platzbecker Sebastian Schwind Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
description	Background: For most patients with acute myeloid leukemia (AML) harboring a trisomy 8 an allogeneic hematopoietic stem cell transplantation (HSCT) is a suitable and recommended consolidation therapy. However, comparative outcome analyses between patients with and without trisomy 8 undergoing allogeneic HSCT have not been performed so far. Methods: We retrospectively analyzed clinical features, outcomes, and measurable residual disease (MRD) of 659 AML (12%, <i>n</i> = 81, with a trisomy 8) patients subjected to allogeneic HSCT as a consolidation therapy. Results: The presence of a trisomy 8 associated with a trend for higher age at diagnosis, AML of secondary origin, lower white blood cell counts at diagnosis, worse ELN2017 genetic risk, wild-type <i>NPM1</i>, and mutated <i>IDH1/2</i> and <i>JAK2</i>. Outcomes after allogeneic HSCT in the entire cohort did not differ between patients with a sole trisomy 8, trisomy 8 with additional cytogenetic aberrations or without a trisomy 8. A trisomy 8 did not affect outcomes within the three ELN2017 risk groups. In accordance with findings in unselected patient cohorts, persistent MRD at allogeneic HSCT in patients with a trisomy 8 identified individuals with a higher risk of relapse following allogeneic HSCT. Conclusions: Outcomes of trisomy 8 patients after allogeneic HSCT did not compare unfavorably to that of other AML patients following allogeneic HSCT. Rather than the presence or absence of a trisomy 8, additional genetic aberrations and MRD at HSCT define outcome differences and aid in informed treatment decisions.
format	article
author	Donata Backhaus Madlen Jentzsch Lara Bischof Dominic Brauer Christina Wilhelm Julia Schulz Georg-Nikolaus Franke Wolfram Pönisch Vladan Vucinic Uwe Platzbecker Sebastian Schwind
author_facet	Donata Backhaus Madlen Jentzsch Lara Bischof Dominic Brauer Christina Wilhelm Julia Schulz Georg-Nikolaus Franke Wolfram Pönisch Vladan Vucinic Uwe Platzbecker Sebastian Schwind
author_sort	Donata Backhaus
title	Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
title_short	Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
title_full	Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
title_fullStr	Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
title_full_unstemmed	Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
title_sort	risk stratification, measurable residual disease, and outcomes of aml patients with a trisomy 8 undergoing allogeneic hematopoietic stem cell transplantation
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/797cdbdae53349c79acd6c63e269a2f6
work_keys_str_mv	AT donatabackhaus riskstratificationmeasurableresidualdiseaseandoutcomesofamlpatientswithatrisomy8undergoingallogeneichematopoieticstemcelltransplantation AT madlenjentzsch riskstratificationmeasurableresidualdiseaseandoutcomesofamlpatientswithatrisomy8undergoingallogeneichematopoieticstemcelltransplantation AT larabischof riskstratificationmeasurableresidualdiseaseandoutcomesofamlpatientswithatrisomy8undergoingallogeneichematopoieticstemcelltransplantation AT dominicbrauer riskstratificationmeasurableresidualdiseaseandoutcomesofamlpatientswithatrisomy8undergoingallogeneichematopoieticstemcelltransplantation AT christinawilhelm riskstratificationmeasurableresidualdiseaseandoutcomesofamlpatientswithatrisomy8undergoingallogeneichematopoieticstemcelltransplantation AT juliaschulz riskstratificationmeasurableresidualdiseaseandoutcomesofamlpatientswithatrisomy8undergoingallogeneichematopoieticstemcelltransplantation AT georgnikolausfranke riskstratificationmeasurableresidualdiseaseandoutcomesofamlpatientswithatrisomy8undergoingallogeneichematopoieticstemcelltransplantation AT wolframponisch riskstratificationmeasurableresidualdiseaseandoutcomesofamlpatientswithatrisomy8undergoingallogeneichematopoieticstemcelltransplantation AT vladanvucinic riskstratificationmeasurableresidualdiseaseandoutcomesofamlpatientswithatrisomy8undergoingallogeneichematopoieticstemcelltransplantation AT uweplatzbecker riskstratificationmeasurableresidualdiseaseandoutcomesofamlpatientswithatrisomy8undergoingallogeneichematopoieticstemcelltransplantation AT sebastianschwind riskstratificationmeasurableresidualdiseaseandoutcomesofamlpatientswithatrisomy8undergoingallogeneichematopoieticstemcelltransplantation
_version_	1718412784418422784

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Ejemplares similares